<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04968249</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00176147</org_study_id>
    <nct_id>NCT04968249</nct_id>
  </id_info>
  <brief_title>Michigan Early Disease Progression Cohort</brief_title>
  <acronym>MAP_COPD</acronym>
  <official_title>Michigan eArly Disease Progression Cohort in COPD (MAP COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this project is to develop a disease progression cohort within the University of&#xD;
      Michigan Health System to capture pulmonary function, symptom assessments and quantitative&#xD;
      imaging among patients at risk for or with an established diagnosis of COPD, focusing however&#xD;
      on &quot;early&quot; COPD (age 30-55 and GOLD stage 0,1, 2, and prism).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants between the ages of 30-55 with at least 10 pack-year smoking history will be&#xD;
      enrolled into a observational longitudinal cohort.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 30, 2021</start_date>
  <completion_date type="Anticipated">July 2026</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>CAAT score ≥ 10</measure>
    <time_frame>18 months</time_frame>
    <description>Proportion of individuals with CAAT score ≥ 10</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Exacerbations in the prior year</measure>
    <time_frame>18 months</time_frame>
    <description>Frequency of moderate and severe exacerbations in the prior year measured at baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiographic abnormalities on baseline CT</measure>
    <time_frame>18 months</time_frame>
    <description>Proportion of individuals with radiographic abnormality on baseline CT defined as PRMfSAD≥15% and/or PRMEmph ≥3%</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Gold 0</arm_group_label>
    <description>Participant must be ages 30-55 years; and have: ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC &gt; 0.70 and FEV1 &gt; 80% predicted; and COPD Assessment Test (CAT) score ≥ 10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gold 1</arm_group_label>
    <description>Participants shall be between ages 30-55 years, and have: ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC &lt; 0.70 and FEV1 &gt;= 80% predicted.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gold 2</arm_group_label>
    <description>Participants shall be between ages 30-55 years, and have: ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC &lt; 0.70 and FEV1 50-79% predicted.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prism</arm_group_label>
    <description>Participant must a &gt;10 year smoking history, post-bronchodilator of FEV1 &lt;80%, and a predicted DEV1/FVC &gt;.70</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational</intervention_name>
    <description>Observational Cohort to understand risk factors for early COPD.</description>
    <arm_group_label>Gold 0</arm_group_label>
    <arm_group_label>Gold 1</arm_group_label>
    <arm_group_label>Gold 2</arm_group_label>
    <arm_group_label>Prism</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, plasma, and nasal swabs.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients meeting inclusion criteria who have established disease as well as smokers meeting&#xD;
        inclusion criteria where pulmonary function testing has not been performed.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  GOLD 0 participants shall be ages 30-55 years; and have: ≥ 10 pack-year smoking&#xD;
             history; post-bronchodilator FEV1/FVC &gt; 0.70 and FEV1 &gt; 80% predicted; and COPD&#xD;
             Assessment Test (CAT) score ≥ 10.&#xD;
&#xD;
          -  Preserved Ratio Impaired Spirometry (PRISm) participants shall be between ages 30-55&#xD;
             years; and have: ≥ 10 pack-year smoking history; post-bronchodilator FEV1 &lt; 80%&#xD;
             predicted FEV1/FVC &gt; 0.70.&#xD;
&#xD;
          -  GOLD 1-2 participants shall be between ages 30-55 years, and have: ≥ 10 pack-year&#xD;
             smoking history; post-bronchodilator FEV1/FVC &lt; 0.70 and FEV1 50-80% predicted.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe asthma, which is defined as any of the following:&#xD;
&#xD;
        Current (i.e., at the time of the visit) GINA Step 4 or higher therapy (medium dose&#xD;
        ICS/LABA or high dose ICS or add-on LAMA; Medium dose = &gt;250 fluticasone propionate =100&#xD;
        fluticasone furoate, &gt;200 beclomethasone, &gt;400 budesonide, &gt;220 mometasone). We will accept&#xD;
        low-dose ICS/LABA or medium dose ICS.&#xD;
&#xD;
        or 3 or more unscheduled healthcare visits (provider/urgent care/ER) for asthma in the past&#xD;
        12 months or One asthma hospitalization in the past 12 months&#xD;
&#xD;
          -  Concurrent participation in a therapeutic trial where treatment is blinded.&#xD;
&#xD;
          -  Active pregnancy at the time of the baseline or return visits. This special population&#xD;
             is being excluded to minimize potential for fetal radiation exposure.&#xD;
&#xD;
          -  Cognitive dysfunction that prevents the participant from completing study procedures.&#xD;
&#xD;
          -  BMI &gt; 35.0 kg/m2 at baseline, due to the effects of body weight on CT scan imaging&#xD;
             quality.&#xD;
&#xD;
          -  The presence of a respiratory condition other than COPD or asthma, or of a comorbid&#xD;
             condition that in the judgment of the investigator may be the principal cause of&#xD;
             respiratory symptoms (e.g., dyspnea or decreased exercise tolerance).&#xD;
&#xD;
          -  Any illness expected to cause mortality in the next 3 years.&#xD;
&#xD;
          -  Any implanted metallic devices or prosthesis above the waist that could degrade&#xD;
             thoracic CT scan image quality.&#xD;
&#xD;
          -  History of thoracic radiation or thoracic surgery with resection of lung tissue&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MeiLan Han</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan, Michigan Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stacey Anderson</last_name>
    <phone>734-763-7810</phone>
    <email>staceaan@med.umich.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer Mawby</last_name>
    <phone>734-763-7810</phone>
    <email>jlmawby@MED.UMICH.EDU</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gretchen Bautista</last_name>
      <phone>734-764-8146</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Martinez FJ, Han MK, Allinson JP, Barr RG, Boucher RC, Calverley PMA, Celli BR, Christenson SA, Crystal RG, Fagerås M, Freeman CM, Groenke L, Hoffman EA, Kesimer M, Kostikas K, Paine R 3rd, Rafii S, Rennard SI, Segal LN, Shaykhiev R, Stevenson C, Tal-Singer R, Vestbo J, Woodruff PG, Curtis JL, Wedzicha JA. At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2018 Jun 15;197(12):1540-1551. doi: 10.1164/rccm.201710-2028PP. Erratum in: Am J Respir Crit Care Med. 2018 Dec 1;198(11):1463.</citation>
    <PMID>29406779</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 8, 2021</study_first_submitted>
  <study_first_submitted_qc>July 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2021</study_first_posted>
  <last_update_submitted>November 7, 2021</last_update_submitted>
  <last_update_submitted_qc>November 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>MeiLan Han</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Early COPD</keyword>
  <keyword>COPD</keyword>
  <keyword>Smoking</keyword>
  <keyword>CAPTURE</keyword>
  <keyword>RETHINC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

